These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Plans-Rubió P Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328 [TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of the English smoking treatment services: evidence from practice. Godfrey C; Parrott S; Coleman T; Pound E Addiction; 2005 Apr; 100 Suppl 2():70-83. PubMed ID: 15844290 [TBL] [Abstract][Full Text] [Related]
27. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Johannesson M; Hedbrant J; Jönsson B Med Inform (Lond); 1991; 16(4):355-62. PubMed ID: 1762471 [TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. Finkelstein EA; Troped PJ; Will JC; Palombo R J Womens Health Gend Based Med; 2002; 11(6):519-26. PubMed ID: 12243129 [TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of screening for oral cancer in primary care. Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071 [TBL] [Abstract][Full Text] [Related]
31. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Stone PW; Teutsch S; Chapman RH; Bell C; Goldie SJ; Neumann PJ Am J Prev Med; 2000 Jul; 19(1):15-23. PubMed ID: 10865159 [TBL] [Abstract][Full Text] [Related]
32. Who should be screened for HIV infection? A cost-effectiveness analysis. McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077 [TBL] [Abstract][Full Text] [Related]
33. [Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources]. Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE Lakartidningen; 1999 Jun; 96(23):2858-63, 2865-6. PubMed ID: 10405534 [TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands. Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351 [TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of coronary heart disease prevention strategies in adults. Brown AD; Garber AM Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251 [TBL] [Abstract][Full Text] [Related]
37. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. Milne RJ; Vander Hoorn S; Jackson RT Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463 [TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of forty health interventions in Guinea. Jha P; Bangoura O; Ranson K Health Policy Plan; 1998 Sep; 13(3):249-62. PubMed ID: 10187595 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Grover SA; Coupal L; Paquet S; Zowall H Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]